微芯生物：关于2021年股票增值权激励计划第四个行权期不符合行权条件暨作废该部分股票增值权的公告

Core Points - Microchip Biotech announced the cancellation of stock appreciation rights due to unmet performance targets [2] - The company failed to meet the revenue growth rate required for the 2021 stock appreciation rights incentive plan [2] - A total of 12,500 stock appreciation rights will be rendered void, affecting one incentive recipient [2]